303 related articles for article (PubMed ID: 15562376)
1. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.
Smith SR; De Jonge L; Volaufova J; Li Y; Xie H; Bray GA
Metabolism; 2005 Jan; 54(1):24-32. PubMed ID: 15562376
[TBL] [Abstract][Full Text] [Related]
2. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes.
Shah PK; Mudaliar S; Chang AR; Aroda V; Andre M; Burke P; Henry RR
Diabetes Obes Metab; 2011 Jun; 13(6):505-10. PubMed ID: 21272186
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
[TBL] [Abstract][Full Text] [Related]
4. Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.
Rajeev SP; Sprung VS; Roberts C; Harrold JA; Halford JC; Stancak A; Boyland EJ; Kemp GJ; Cuthbertson DJ; Wilding JP
BMJ Open; 2017 Jan; 7(1):e013539. PubMed ID: 28132008
[TBL] [Abstract][Full Text] [Related]
5. Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone.
Kushner RF; Sujak M
Obesity (Silver Spring); 2009 May; 17(5):1017-22. PubMed ID: 19180065
[TBL] [Abstract][Full Text] [Related]
6. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.
Bray GA; Smith SR; Banerji MA; Tripathy D; Clement SC; Buchanan TA; Henry RR; Kitabchi AE; Mudaliar S; Musi N; Ratner RE; Schwenke DC; Stentz FB; Reaven PD; DeFronzo RA
Diabetes Obes Metab; 2013 Oct; 15(10):931-7. PubMed ID: 23551856
[TBL] [Abstract][Full Text] [Related]
7. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
8. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
9. No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE).
Rajeev SP; Roberts CA; Brown E; Sprung VS; Harrold JA; Halford JCG; Stancak A; Boyland EJ; Kemp GJ; Perry J; Howarth E; Jackson R; Wiemken A; Schwab R; Cuthbertson DJ; Wilding JPH
Diabetes Obes Metab; 2023 Dec; 25(12):3621-3631. PubMed ID: 37667658
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone reduces cold-induced brown fat glucose uptake despite induction of browning in cultured human adipocytes: a randomised, controlled trial in humans.
Loh RKC; Formosa MF; Eikelis N; Bertovic DA; Anderson MJ; Barwood SA; Nanayakkara S; Cohen ND; La Gerche A; Reutens AT; Yap KS; Barber TW; Lambert GW; Cherk MH; Duffy SJ; Kingwell BA; Carey AL
Diabetologia; 2018 Jan; 61(1):220-230. PubMed ID: 29046921
[TBL] [Abstract][Full Text] [Related]
11. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
[TBL] [Abstract][Full Text] [Related]
12. Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
Kodama N; Tahara N; Tahara A; Honda A; Nitta Y; Mizoguchi M; Kaida H; Ishibashi M; Abe T; Ikeda H; Narula J; Fukumoto Y; Yamagishi S; Imaizumi T
J Clin Endocrinol Metab; 2013 Nov; 98(11):4438-45. PubMed ID: 24030946
[TBL] [Abstract][Full Text] [Related]
13. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
14. The effect of pioglitazone and resistance training on body composition in older men and women undergoing hypocaloric weight loss.
Shea MK; Nicklas BJ; Marsh AP; Houston DK; Miller GD; Isom S; Miller ME; Carr JJ; Lyles MF; Harris TB; Kritchevsky SB
Obesity (Silver Spring); 2011 Aug; 19(8):1636-46. PubMed ID: 21233810
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial.
Grey A; Beckley V; Doyle A; Fenwick S; Horne A; Gamble G; Bolland M
Eur J Endocrinol; 2012 Jun; 166(6):1087-91. PubMed ID: 22408124
[TBL] [Abstract][Full Text] [Related]
16. Weight gain in type 2 diabetes mellitus.
Jacob AN; Salinas K; Adams-Huet B; Raskin P
Diabetes Obes Metab; 2007 May; 9(3):386-93. PubMed ID: 17391167
[TBL] [Abstract][Full Text] [Related]
17. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
Smith RC; Jin H; Li C; Bark N; Shekhar A; Dwivedi S; Mortiere C; Lohr J; Hu Q; Davis JM
Schizophr Res; 2013 Jan; 143(1):18-24. PubMed ID: 23200554
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
[TBL] [Abstract][Full Text] [Related]
19. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
Chiquette E; Ramirez G; Defronzo R
Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]